Aridis Pharmaceuticals Stock News

Making a penny stocks watchlist today? Check these three out The post Best Penny Stocks to Buy as 2021 Ends?

Aridis Pharmaceuticals Inc (NASDAQ: ARDS) stock is surging after announcing encouraging preclinical data for pan coronavirus fully human monoclonal antibody (mAb) cocktail AR-701. The data show that

The stock price of Aridis Pharmaceuticals Inc (NASDAQ: ARDS) increased by over 105% pre-market today. This is why it happened.

Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) saw a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 5,100 shares, a decrease of 67.1% from the October 31st total of 15,500 shares. Currently, 0.1% of the shares of the company are short sold. Based on an average trading []

ARDS, CNNE, EXK, GP, and IFF have been added to the Zacks Rank #5 (Strong Sell) List on November 15, 2021.

Aridis Pharmaceuticals (NASDAQ:ARDS) had its price objective cut by Northland Securities from $22.00 to $10.00 in a report released on Thursday morning, The Fly reports. They currently have an outperform rating on the stock. ARDS has been the subject of several other research reports. Zacks Investment Research downgraded shares of Aridis Pharmaceuticals from a buy []

Aridis Pharmaceuticals (NASDAQ:ARDS) had its target price decreased by Northland Securities from $22.00 to $10.00 in a report issued on Thursday, The Fly reports. Northland Securities currently has an outperform rating on the stock. ARDS has been the subject of several other research reports. Zacks Investment Research downgraded shares of Aridis Pharmaceuticals from a buy []

ARIDIS PHARMACT (ARDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LOS GATOS, Calif., Aug. 2, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to

LOS GATOS, Calif., July 26, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to

Aridis Pharmaceuticals Inc (NASDAQ: ARDS) has announced that its COVID-19 mAb cocktail AR-712 binds and neutralizes the Delta variant of COVID-19 at a highly effective level (~20ng/mL).  Binding a

LOS GATOS, Calif., July 12, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to

ARIDIS PHARMACT (ARDS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more str

LOS GATOS, Calif., May 11, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to